PEGYLATED PROTEINS MARKET ANALYSIS

PEGylated Proteins Market, by Type (Consumables and Services), by Protein (Colony-stimulating factor, Interferons, Erythropoietin, Recombinant factor VII and Other), by Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder and Others), by End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations and Academic Research Institutes), and by (Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5354
Pages :196
Formats :
Excel and PDF
Industry : Biotechnology

Market News

Global PEGylated Proteins Market: Key Developments

In September 2020, Humanigen, Inc., a clinical-stage biopharmaceutical company, and Lonza, a multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, a GM-CSF neutralising monoclonal antibody, currently in Phase 3 clinical trials for COVID-19.

In February 2021, Biogen, a multinational biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS).

PEGylated Proteins Market Report Snapshots